Literature DB >> 24440278

How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study.

Aliya N Husain1, M Kamran Mirza2, Allen Gibbs3, Kenzo Hiroshima4, Yiqing Chi2, Redouane Boumendjel2, Nolwenn Stang5, Thomas Krausz2, Francoise Galateau-Salle5.   

Abstract

OBJECTIVE: Mesothelial hyperplasia (MH) and fibrosing pleuritis (FP) can be difficult to distinguish from epithelioid (MM-E) and sarcomatoid (MM-S) malignant pleural mesotheliomas. GLUT-1 has shown variable results regarding its sensitivity and specificity when used to evaluate mesothelial proliferations. We evaluated the utility of GLUT-1 immunostaining in differentiating MH and FP from MM-E and MM-S.
MATERIALS AND METHODS: In this retrospective study, diagnostically well-characterized cases (MH=31, FP=29, MM-E=41, MM-S=29) were collected and manually stained for GLUT-1. All slides were visually scored by 2 pathologists; using the following system: 0%, 1+ 1-25%, 2+ 26-50% and 3+ >51% cells staining.
RESULTS: All benign cases (n=60) were negative for GLUT-1 while 45 of 78 (58%) MM [21 of 41 (50%) MM-E, 21 of 29 (72%) MM-S and 3 of 3 biphasic mesothelioma (100%)] had 1+ to 3+ staining. Of the MM-E, 10 had 1+, and 11 had 2+ staining; of the MM-S 3 had 1+, 15 had 2+ and 3 had 3+ staining. Both sarcomatoid and epithelioid components of the 3 biphasic mesotheliomas revealed 1+ staining. All 5 desmoplastic MM were negative.
CONCLUSIONS: Positive staining with GLUT-1 is helpful since it is present in half of MM-E and three-quarter of MM-S. Although all reactive mesothelial lesions were negative, the absence of immunoreactivity does not exclude the diagnosis of MM. As with all IHC stains used for diagnostic purposes, GLUT-1 has to be a part of a panel, and the results interpreted in the context of clinical, radiological and histological findings.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Epithelioid mesothelioma; Fibrosing pleuritis; GLUT-1; Malignant mesothelioma; Mesothelial hyperplasia; Sarcomatoid mesothelioma

Mesh:

Substances:

Year:  2013        PMID: 24440278     DOI: 10.1016/j.lungcan.2013.12.009

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  3 in total

Review 1.  The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review.

Authors:  Greta Alì; Rossella Bruno; Gabriella Fontanini
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

2.  BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.

Authors:  Marta Cigognetti; Silvia Lonardi; Simona Fisogni; Piera Balzarini; Vilma Pellegrini; Andrea Tironi; Luisa Bercich; Mattia Bugatti; Giulio Rossi; Bruno Murer; Mattia Barbareschi; Silvia Giuliani; Alberto Cavazza; Gianpietro Marchetti; William Vermi; Fabio Facchetti
Journal:  Mod Pathol       Date:  2015-05-29       Impact factor: 7.842

Review 3.  Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology.

Authors:  Anders Hjerpe; Valeria Ascoli; Carlos Bedrossian; Mathilde Boon; Jenette Creaney; Ben Davidson; Annika Dejmek; Katalin Dobra; Ambrogio Fassina; Andrew Field; Pinar Firat; Toshiaki Kamei; Tadao Kobayashi; Claire W Michael; Sevgen Önder; Amanda Segal; Philippe Vielh
Journal:  Cytojournal       Date:  2015-11-30       Impact factor: 2.091

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.